News | August 10, 2024
Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Subscribe To Our Newsletter & Stay Updated
